| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Novartis is making significant strides in Product/Service Development, particularly through the expansion of treatment options such as its Cosentyx therapy, which now includes indications for adolescents with hidradenitis suppurativa. Advances in its dermatology portfolio and a focus on precision medicine in oncology highlight the company’s strategic direction towards targeted therapies. The acquisition and development of innovative cancer treatments further signify Novartis’s commitment to enhancing its product offerings and ensuring sustained growth. Overall, these efforts position Novartis favorably in an increasingly competitive healthcare landscape. |
| The price action of Novartis AG (NVS) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -2.3 is extremely bearish. The market sentiment at 0.6 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for NVS since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1.3, and the negative at -0.7 on 2026-03-20. The forces of Stock Price Trend (-2.3), Sector Price Trend (-1.7), and Valuation Sentiment (-1) will drive down the price. The forces of Market Risk Appetite (0), Price Level Sentiment (1), Option Sentiment (1.5), and Sentiment towards Fundamentals (5.1) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| NVS | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | 0%(0%) | 146.06 | 4.61% | -0 | -1.44% | -0.9% | -2.3 | -0.3 | 1.2% | 0.6 | Short | 70% | 5.1 | 6 |
| 2026-03-19 | 0%(0%) | 148.2 | 4.05% | -1 | -1.08% | -0.83% | -2.2 | -0.5 | 2% | 0.6 | Short | 70% | 4.9 | -1 |
| 2026-03-18 | 0%(0%) | 149.82 | 3.56% | -3 | -3.25% | -0.95% | -2.3 | -0.7 | 1.4% | -0.1 | Short | 70% | 2.9 | -1 |
| 2026-03-17 | 0%(0%) | 154.86 | 3.05% | 12 | 0% | -0.56% | -1.8 | 0.1 | 0.4% | -0.4 | Short | 65% | 1.4 | -1 |
| 2026-03-16 | 0%(0%) | 154.86 | 2.91% | 7 | 0.9% | -0.75% | -2.1 | 0.2 | 0.4% | -0.7 | Wait | 50% | 0.8 | -1 |
| 2026-03-15 | 0%(0%) | -2 | 0.2 | -0.9 | -0.5 | -1 | ||||||||
| 2026-03-14 | 0%(0%) | -2 | 0.2 | -0.9 | -0.5 | -1 | ||||||||
| 2026-03-13 | 0%(0%) | 153.48 | 2.7% | -7 | -0.53% | -0.99% | -2 | -0.3 | 0.5% | -0.5 | Short | 70% | -0.5 | -1 |
| 2026-03-12 | 0%(0%) | 154.3 | 2.31% | -14 | -0.97% | -0.67% | -1.8 | -0.3 | 2% | -0.8 | Short | 70% | -0.7 | -1 |
| 2026-03-11 | 0%(0%) | 155.8 | 1.93% | -16 | -3.61% | -0.67% | -2 | -0.6 | 1.8% | -0.9 | Short | 70% | 0.3 | -1 |
| Short is the preferred trading strategy with 70% chance of being right. Both trend sentiment and hourly trend are very weak. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Novartis AG (NVS) Equity Research Report Wed. Mar 11, 2026 | ||
| 2026-03-20 17:14:20 Recent fluctuations in Novartis's stock price may be influenced by its ongoing investments and developments in the oncology sector, impacting investor sentiment. |
| 2026-03-20 17:14:20 The emphasis on developing and acquiring innovative cancer therapies demonstrates Novartis's commitment to expanding its product offerings and driving future growth. |
| 2026-03-20 17:14:20 Novartis's focus on precision oncology and targeted therapies reflects a broader industry trend towards personalized medicine in cancer treatment. |
| 2026-03-20 17:14:20 The acquisition of the breast cancer drug candidate SNV4818 highlights Novartis's strategy to enhance its pipeline through partnerships with biotechnology firms. |
| 2026-03-20 17:14:20 Novartis is making significant investments in oncology, particularly in breast cancer treatments, indicating a strong focus on expanding its portfolio in this therapeutic area. |
| 2026-03-20 11:49:45 The $3 billion investment reflects the growing emphasis on developing advanced cancer treatments and the potential for financial returns. |
| 2026-03-20 11:49:45 The focus on PIK3CA-mutated breast cancer illustrates a trend towards precision medicine in the oncology field. |
| 2026-03-20 11:49:45 Novartis's acquisition of the breast cancer drug SNV4818 represents a strategic partnership aimed at enhancing its portfolio with a next-generation treatment. |